VGX Pharmaceuticals (Formerly Known as Viral Genomix, Inc.) Announces Filing of Device Master File Amendment with the FDA for CELLECTRA Device – Intradermal Electroporation (ID-EP)

BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals today announced the filing of a Device Master File (MAF) amendment with the U.S. Food and Drug Administration (FDA) for its patented CELLECTRA® adaptive constant current electroporation device for use with intradermal electroporation (ID-EP). The Company has been developing the CELLECTRA® device as its lead clinical device for delivering DNA vaccine and therapy products. Numerous preclinical efficacy studies have shown that delivery of DNA-based product candidates with the CELLECTRA® device optimizes DNA uptake and its subsequent expression in the target tissue, and results in enhanced immune responses in animals.